Guardant Health Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health or view top-rated stocks.

Wall Street analysts have given Guardant Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Guardant Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Guardant Health.

Guardant Health will be holding an earnings conference call on Thursday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Guardant Health, Inc. (NASDAQ:GH) posted its quarterly earnings data on Wednesday, February, 24th. The company reported ($0.94) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.50. The business had revenue of $78.32 million for the quarter, compared to analysts' expectations of $77.75 million. Guardant Health had a negative trailing twelve-month return on equity of 19.22% and a negative net margin of 67.14%.
View Guardant Health's earnings history.

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GH shares have increased by 151.8% and is now trading at $158.50.
View which stocks have been most impacted by COVID-19.

Guardant Health updated its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $360-370 million, compared to the consensus revenue estimate of $377.07 million.

9 brokerages have issued 1 year target prices for Guardant Health's stock. Their forecasts range from $135.00 to $195.00. On average, they anticipate Guardant Health's share price to reach $170.50 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price.
View analysts' price targets for Guardant Health or view top-rated stocks among Wall Street analysts.

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Guardant Health include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Natera (NTRA), Invitae (NVTA), Elekta AB (publ) (EKTAY), CareDx (CDNA), Veracyte (VCYT), Burning Rock Biotech (BNR), Fulgent Genetics (FLGT), Genetron (GTH), Castle Biosciences (CSTL), DermTech (DMTK), RadNet (RDNT), Personalis (PSNL) and Renalytix AI (RNLX).
View all of GH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), The Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Chicago Capital LLC (0.25%), Carnegie Capital Asset Management LLC (0.10%), FDx Advisors Inc. (0.00%), Valeo Financial Advisors LLC (0.00%) and NEXT Financial Group Inc (0.00%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health.

GH stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, FDx Advisors Inc., and NEXT Financial Group Inc. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health or view top insider-selling stocks.

GH stock was bought by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC, and Valeo Financial Advisors LLC.
View insider buying and selling activity for Guardant Health or or view top insider-buying stocks.

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GH stock can currently be purchased for approximately $158.50.

Guardant Health has a market capitalization of $15.92 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

Guardant Health employs 864 workers across the globe.

The official website for Guardant Health is www.guardanthealth.com.

Guardant Health is headquartered at 505 PENOBSCOT DR., REDWOOD CITY CA, 94063.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.